Dyne Therapeutics, Inc. (DYN): Price and Financial Metrics
DYN Price/Volume Stats
| Current price | $23.86 | 52-week high | $30.27 |
| Prev. close | $23.65 | 52-week low | $6.40 |
| Day low | $23.11 | Volume | 973,200 |
| Day high | $24.21 | Avg. volume | 2,024,588 |
| 50-day MA | $25.90 | Dividend yield | N/A |
| 200-day MA | $15.23 | Market Cap | 2.06B |
DYN Stock Price Chart Interactive Chart >
Dyne Therapeutics, Inc. (DYN) Company Bio
Dyne Therapeutics, Inc. operates as a biotechnology company. The Company focuses on transforming the lives of people with serious diseases by developing muscle-targeted therapies. Dyne Therapeutics offers its services in the United States.
Latest DYN News From Around the Web
Below are the latest news stories about DYNE THERAPEUTICS INC that investors may wish to consider to help them evaluate DYN as an investment opportunity.
3 of the Best Cheap Stocks Under $20 to Buy Now: November EditionAfter dropping to 52-week lows, the markets have been rallying, sending traders and investors are looking for cheap stocks under $20. |
Dyne Therapeutics to Present at November Investor ConferencesWALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following investor conferences in November: Stifel 2023 Healthcare Conference, fireside chat on Tuesday, November 14, 2023 at 4:45 p.m. ET in New York Piper Sandler 35th Annual Healthcare Confe |
Dyne Therapeutics Inc (DYN) Reports Q3 2023 Financial Results and Progress in Clinical TrialsCompany's cash position remains strong, R&D expenses increase, and net loss widens |
The Dyne Therapeutics Inc (DYN) Company: A Short SWOT AnalysisUnveiling the Strengths, Weaknesses, Opportunities, and Threats of Dyne Therapeutics Inc |
Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones- Initial ACHIEVE and DELIVER Data to be Presented at a Company Event Around the J.P. Morgan Healthcare Conference in Early January 2024, Including Safety, Biomarker of Splicing and Functional Outcome of Myotonia in DM1; Safety and Dystrophin Expression in DMD - - ACHIEVE Trial of DYNE-101 in DM1 Fully Enrolled Through 3.4 mg/kg Cohort;DELIVER Trial of DYNE-251 in DMD Fully Enrolled Through 10 mg/kg Cohort - - Safety Profile in ACHIEVE and DELIVER Has Supported Dose Escalation to a Combined Nine |
DYN Price Returns
| 1-mo | -14.51% |
| 3-mo | 52.75% |
| 6-mo | 229.10% |
| 1-year | 127.24% |
| 3-year | 37.68% |
| 5-year | N/A |
| YTD | 79.40% |
| 2023 | 14.75% |
| 2022 | -2.52% |
| 2021 | -43.38% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...